- Home
- SNTI vs XCUR Comparison
SNTI vs XCUR Comparison
Compare SNTI & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- XCUR
- Stock Information
- Founded
- SNTI 2016
- XCUR 2011
- Country
- SNTI United States
- XCUR United States
- Employees
- SNTI N/A
- XCUR N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- XCUR Biotechnology: Pharmaceutical Preparations
- Sector
- SNTI Health Care
- XCUR Health Care
- Exchange
- SNTI Nasdaq
- XCUR Nasdaq
- Market Cap
- SNTI 39.6M
- XCUR 32.4M
- IPO Year
- SNTI N/A
- XCUR N/A
- Fundamental
- Price
- SNTI $1.39
- XCUR $3.88
- Analyst Decision
- SNTI Strong Buy
- XCUR
- Analyst Count
- SNTI 2
- XCUR 0
- Target Price
- SNTI $8.50
- XCUR N/A
- AVG Volume (30 Days)
- SNTI 121.1K
- XCUR 29.2K
- Earning Date
- SNTI 11-13-2025
- XCUR 11-13-2025
- Dividend Yield
- SNTI N/A
- XCUR N/A
- EPS Growth
- SNTI N/A
- XCUR N/A
- EPS
- SNTI N/A
- XCUR N/A
- Revenue
- SNTI N/A
- XCUR N/A
- Revenue This Year
- SNTI N/A
- XCUR N/A
- Revenue Next Year
- SNTI $150.00
- XCUR N/A
- P/E Ratio
- SNTI N/A
- XCUR N/A
- Revenue Growth
- SNTI N/A
- XCUR N/A
- 52 Week Low
- SNTI $1.26
- XCUR $2.07
- 52 Week High
- SNTI $16.94
- XCUR $36.00
- Technical
- Relative Strength Index (RSI)
- SNTI 39.50
- XCUR 31.08
- Support Level
- SNTI $1.33
- XCUR $3.55
- Resistance Level
- SNTI $1.42
- XCUR $4.21
- Average True Range (ATR)
- SNTI 0.07
- XCUR 0.38
- MACD
- SNTI 0.02
- XCUR -0.04
- Stochastic Oscillator
- SNTI 44.83
- XCUR 29.86
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.